Verastem, Inc.(VSTM)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,522 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
Unusual Activity in VSTM
Events flagged as statistical outliers against VSTM's own multi-year baseline — not fixed dollar thresholds.
- Score shock2026-08-06
VSTM quality score dropped 12 points (41→29) on a new filing
View source filing →
VSTM Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Verastem, Inc. (VSTM), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores VSTM at 29.7/100 on a 32-signal composite quality model, placing it at rank #2,522 of 2,962 stocks — the bottom half of the AI-ranked universe. VSTM scores in the top quartile across revenue growth (95.8), institutional flow (93.0). Areas of concern include balance sheet strength (1.0) and free cash flow (4.1), which score below median versus the broader universe. Shareholder dilution risk is elevated at 6.3/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Verastem, Inc. reports quarterly revenue of $40.1M, net income of $-34.7M. Top institutional holders of VSTM by reported 13-F value include BlackRock, ARMISTICE CAPITAL, RTW INVESTMENTS, based on the most recent SEC filings. VSTM trades on the Nasdaq exchange and files with the SEC under CIK 1526119. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate VSTM daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Verastem, Inc. directly from SEC EDGAR. Verastem, Inc.'s 13F Pro composite quality score has ranged between 7 and 43 since 2021, currently 29.7 — a declining long-term trajectory across 64 quarterly and live scoring snapshots.
Revenue
Q2 2026
$40.1M
Net Income
Q2 2026
$-34.7M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+209.1% YoYNet Income
-60.3% YoYOperating Income
-48.0% YoYEPS (Diluted)
+17.5% YoYTotal Assets
+142.7% YoYTotal Debt
Op. Cash Flow
-31.2% YoYFree Cash Flow
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $30.9M +209.1% | $10.0M | — | $2.6M +26.4% | $2.1M -97.7% | $88.5M |
| Net Income | $-209.5M -60.3% | $-130.6M -49.5% | $-87.4M -18.4% | $-73.8M -3.7% | $-71.2M -5.1% | $-67.7M |
| Operating Income | $-170.1M -48.0% | $-115.0M -24.8% | $-92.1M -26.3% | $-72.9M -18.8% | $-61.4M -24.4% | $-49.4M |
| EPS (Diluted) | $-3.02 +17.5% | $-3.66 +7.6% | $-3.96 -939.9% | $-0.38 +6.7% | $-0.41 -1012.5% | $-0.04 |
| Total Assets | $246.4M +142.7% | $101.5M -32.2% | $149.7M +57.5% | $95.0M -12.5% | $108.7M -29.6% | $154.3M |
| Total Debt | — | $40.7M +1.6% | $40.1M +63.4% | $24.5M | — | — |
| Operating Cash Flow | $-137.5M -31.2% | $-104.8M -21.2% | $-86.5M -35.8% | $-63.7M -19.0% | $-53.5M -59.7% | $-33.5M |
| Free Cash Flow | — | $-104.8M | — | — | $-53.7M -60.1% | $-33.5M |
Get alerted when VSTM's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Verastem, Inc. including:
Top Institutional Holders of VSTM
BlackRock, Inc.
$35.1M9,192,447 shARMISTICE CAPITAL, LLC
$26.8M7,024,000 shRTW INVESTMENTS, LP
$25.3M6,635,793 shDeep Track Capital, LP
$21.9M5,740,850 shSTATE STREET CORP
$19.6M5,133,859 shRosalind Advisors, Inc.
$15.2M3,986,509 shVANGUARD CAPITAL MANAGEMENT LLC
$14.7M3,851,508 shNantahala Capital Management, LLC
$13.7M3,584,820 shStonepine Capital Management, LLC
$12.8M3,349,627 shVANGUARD PORTFOLIO MANAGEMENT LLC
$12.5M3,266,870 sh
| Fund | Value | Shares |
|---|---|---|
| BlackRock, Inc. | $35.1M | 9,192,447 |
| ARMISTICE CAPITAL, LLC | $26.8M | 7,024,000 |
| RTW INVESTMENTS, LP | $25.3M | 6,635,793 |
| Deep Track Capital, LP | $21.9M | 5,740,850 |
| STATE STREET CORP | $19.6M | 5,133,859 |
| Rosalind Advisors, Inc. | $15.2M | 3,986,509 |
| VANGUARD CAPITAL MANAGEMENT LLC | $14.7M | 3,851,508 |
| Nantahala Capital Management, LLC | $13.7M | 3,584,820 |
| Stonepine Capital Management, LLC | $12.8M | 3,349,627 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $12.5M | 3,266,870 |
Companies Similar to VSTM
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
CG Oncology, Inc.
Kura Oncology, Inc.
Ultragenyx Pharmaceutical Inc.
ANAPTYSBIO, INC
RHYTHM PHARMACEUTICALS, INC.
ARDELYX, INC.
Xeris Biopharma Holdings, Inc.
DELCATH SYSTEMS, INC.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put VSTM on your watchlist
Track score changes the day Verastem, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is VSTM a good stock to buy?
13F Pro's AI-powered analysis of Verastem, Inc. (VSTM) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for VSTM are available on the VSTM stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. VSTM is classified as a small company.
Which hedge funds own VSTM?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling VSTM. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Verastem, Inc.'s investment landscape.